{
  "ticker": "CC5",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02968948",
  "id": "02968948",
  "pages": 2,
  "price_sensitive": true,
  "date": "20250714",
  "time": "0935",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250714/pdf/06lrxdypxrncjw.pdf",
  "summary": "### Key Material Information:  \n- **APAS\u00ae Independence sale** to **Novo Nordisk** for evaluation across its manufacturing network.  \n- **Sales strategy progress**: Engagement with **five multinational pharma companies** (AstraZeneca, Bristol Myers Squibb, Thermo Fisher Pharma Services, Novo Nordisk, and an unnamed fifth customer), representing a **potential 60\u201380 unit sales opportunity**.  \n- **Future outlook**: Expects additional evaluations/sales announcements with large pharmaceutical customers in **FY2026**.  \n\n*No capital raising, trading halt, or financial data disclosed.*",
  "usage": {
    "prompt_tokens": 1263,
    "completion_tokens": 121,
    "total_tokens": 1384,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-13T23:58:50.532706"
}